Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation antigen (BCMA) show success in multiple myeloma.
• Patients with high-risk cytogenetic features in multiple myeloma often experience rapid relapse, necessitating novel therapeutic strategies.

Purpose of the Study:

• To identify novel cell surface antigens for targeted therapy in high-risk multiple myeloma.
• To develop and evaluate an optimized CAR-T design targeting a newly identified antigen.

Main Methods:

• Structure-guided design of a CD27-based anti-CD70 CAR-T.
• In vivo assessment of CAR-T expansion and efficacy.
• Machine learning-based epigenetic analysis to identify drivers of antigen upregulation.

Main Results:

• CD70 was identified as a significantly upregulated antigen in high-risk multiple myeloma.
• The CD27-based anti-CD70 CAR-T demonstrated superior in vivo expansion (>80-fold) compared to scFv-based CARs.
• Epigenetic analysis revealed key transcription factors and networks driving CD70 expression.

Conclusions:

• CD70 is a promising therapeutic target for high-risk multiple myeloma.
• Optimized CD27-based CAR-T designs offer enhanced efficacy and expansion.
• Dual-targeting strategies (e.g., CD70 and BCMA) may overcome antigen escape-mediated resistance, supporting clinical translation.